13F Holdings
中文EN

LNSR LENSAR, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1320350 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY29.3%
TTM net income YoY-292.7%
TTM EPS YoY-289.8%
Revenue 3-yr CAGR16.5%
Net income 3-yr CAGR—

Margins

Gross margin47.2%
Operating margin-25.0%
Net margin-84.5%
FCF margin-9.0%
EBITDA margin-19.3%

Returns

ROE-16,631.7%
ROA-74.8%
ROIC (approx.)—
Asset turnover0.89x

Leverage & solvency

Liabilities / assets113.2%
Debt / equity—
Current ratio1.52x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.10x
Accruals ratio-67.0%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$58.44M$53.49M$42.16M$35.36M$34.46M
Cost of revenue$31.31M$27.64M$21.06M$15.40M$16.63M
Gross profit$27.12M$25.85M$21.11M$19.95M$17.83M
R&D expense$5.62M$5.33M$6.14M$11.81M$12.36M
SG&A expense$45.16M$26.49M$26.10M$27.17M$23.89M
Operating income-$24.58M-$10.66M-$12.23M-$20.18M-$19.65M
Pretax income-$34.28M-$31.40M-$14.38M-$19.91M-$19.60M
Net income-$34.28M-$31.40M-$14.38M-$19.91M-$19.60M
EBITDA-$21.00M-$7.70M-$9.81M-$17.92M-$18.13M
EPS (basic)-2.87-2.73-1.31-1.96-2.09
EPS (diluted)-2.87-2.73-1.31-1.96-2.09
Weighted avg. shares (diluted)11.96M11.52M10.97M10.16M9.37M
Balance sheet
Cash & equivalents$12.97M$16.26M$20.62M$14.67M$31.64M
Short-term investments$5.00M$6.19M$3.44M——
Receivables$6.38M$6.08M$4.00M$6.04M$4.64M
Inventory$21.52M$11.43M$15.69M$11.74M$6.49M
Current assets$46.77M$41.98M$46.44M$33.72M$44.81M
PP&E, net$505,000$664,000$679,000$563,000$756,000
Intangibles$5.19M$6.11M$11.03M$12.12M$10.87M
Total assets$71.43M$66.30M$69.58M$55.84M$66.47M
Current liabilities$40.57M$15.00M$11.63M$11.42M$8.71M
Total liabilities$83.67M$47.65M$22.41M$13.86M$11.59M
Shareholders' equity-$26.02M$4.86M$33.43M$41.98M$54.88M
Shares outstanding11.99M11.65M11.33M11.09M10.99M
Cash flow statement
Operating cash flow-$14.83M-$2.27M-$9.66M-$14.86M-$8.97M
Capital expenditure$83,000$156,000$236,000$115,000$354,000
Free cash flow-$14.91M-$2.43M-$9.89M-$14.97M-$9.32M
Investing cash flow$1.28M-$2.16M-$4.16M-$115,000-$354,000
Financing cash flow$10.26M$78,000$19.76M-$1.99M$361,000
Depreciation & amortization$3.58M$2.96M$2.42M$2.26M$1.52M
Stock-based compensation$3.14M$2.67M$3.14M$6.61M$6.87M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.